# Rapid detection of Golgi protein 73 by MAGLUMI chemiluminescent immunoassay and the clinical value to liver fibrosis/cirrhosis patients with chronic liver disease

## TL;DR

This study shows that a new immunoassay can detect a protein linked to liver disease severity, helping diagnose fibrosis and cirrhosis.

## Contribution

The study introduces a rapid chemiluminescent immunoassay for GP73 and validates its clinical utility in diagnosing liver fibrosis stages.

## Key findings

- GP73 levels significantly increase with liver fibrosis stages (F0-F4) in chronic liver disease patients.
- GP73 shows strong correlation with liver stiffness measurements and METAVIR staging.
- The assay achieves high diagnostic accuracy for cirrhosis (AUC of 0.90).

## Abstract

To investigate the diagnostic value of MAGLUMI chemiluminescent immunoassay (CLIA) for detecting Golgi protein 73 (GP73) in patients with chronic liver disease.

A total of 212 patients with chronic liver disease were selected as the research subjects. METAVIR pathological staging was performed according to LSM values, and GP73 levels were detected by CLIA. Spearman analysis was used to analyze the correlation between GP73, LSM and METAVIR staging. The diagnostic efficacy of GP73 was analyzed using the ROC curve based on METAVIR staging.

The enrolled patients included 37 patients in F0/F1, 80 patients in F2, 61 patients in F3, and 34 patients in F4. There were significant differences in GP73 levels in each stage (p<0.001 for all stages). Spearman correlation analysis showed that GP73 levels were positively correlated with LSM and METAVIR stages. The AUC of GP73 in diagnosing significant liver fibrosis (F≥2), advanced liver fibrosis (F≥3), and cirrhosis (F=4) were 0.78 (95% CI: 0.72~0.84, p<0.0001), 0.83 (95% CI: 0.75~0.89, p<0.0001), 0.90 (95% CI: 0.80~0.96, p<0.0001), respectively.

GP73 detected by CLIA was positively correlated with liver fibrosis stage and LSM, and had important clinical value in diagnosis of liver fibrosis and cirrhosis in patients with chronic liver disease.